TAG-72 specific CH2 domain deleted antibodies
US7319139B2 · kind B2 · utility
21Cited by
17References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 29, 2002 |
| Grant date | Jan 15, 2008 |
| Priority date | — |
| Expiry date | Jan 29, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same antigen binding specificity (homodimers) or, alternatively, may comprise two different antibody molecules having binding specificity for two distinct antigens (heterodimers). In preferred embodiments the antibody molecules comprising the dimers are non-covalently associated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.